A RANDOMIZED PHASE 3 STUDY OF NIVOLUMAB OR PLACEBO COMBINED WITH RADIOTHERAPY PLUS TEMOZOLOMIDE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA WITH METHYLATED MGMT PROMOTER: CHECKMATE 548 Weller, M., Lim, M., Idbaih, A., Steinbach, J., Finocchiaro, G., Raval, R., Ashby, L., Ansstas, G., Baehring, J., Taylor, J., Honnorat, J., Petrecca, K., De Vos, F., Wick, A., Sumrall, A., Roberts, M., Slepetis, R., Warad, D., Lee, M., Reardon, D., Omuro, A. OXFORD UNIV PRESS INC. 2021: 55-56

View details for Web of Science ID 000757356200219